目的 探討原發性干燥綜合征周圍神經病變的發生與干燥綜合征A型/B型抗體（抗SSA/SSB抗體）的關系。 方法 納入2009年1月－2011年12月期間門診及住院收治的原發性干燥綜合征患者88例。所有患者均接受神經系統檢查，采用蛋白質印跡法檢測抗SSA抗體和抗SSB抗體，利用全自動化學發光儀檢測血清維生素B12水平。 結果 88例原發性干燥綜合征患者中有27例（30.7%）存在周圍神經病變。有或無周圍神經病變的患者在年齡、性別、病程等一般情況方面無明顯不同。有周圍神經病變和無周圍神經病變的原發性干燥綜合征患者抗SSA抗體陽性率分別為70.4%（19/27）、70.5%（43/61），差異無統計學意義（χ2=0.000，P=0.991）；抗SSA/SSB抗體雙陽性率分別為63.0%（17/27）、14.8%（9/61），差異有統計學意義（χ2=17.416，P=0.000）；血清維生素B12水平分別為（390 ± 55）、（410 ± 86）pg/dL，差異無統計學意義（t=0.908，P=0.370）。 結論 周圍神經病變在原發性干燥綜合征患者中較常見，且周圍神經病變的發生多伴隨血清抗SSA/SSB抗體陽性。
Objective To make an individualized treatment plan concerning a newborn with meconium aspiration syndrome combined with persistent pulmonary hypertension. Methods Based on the clinical questions raised by a newborn with meconium aspiration syndrome combined with persistent pulmonary hypertension, we searched The Cochrane Library (Issue 3, 2009), MEDLINE (1980 to June 2009), ACP Journal Club (1991 to June 2009), and Chinese Journal Fulltext Database (1994 to June 2009) for systematic reviews, randomized controlled trials (RCTs) and case-control studies. The quality of the included studies was assessed. Results A total of 9 RCTs, 1 health economic evaluation, 1 meta analysis, and 2 systematic reviews were considered eligible. The evidence indicated that the use of ECMO in infants of PPHN had shown a decreased risk of death, but not cost-saving from a societal perspective; iNO treatment could improve the PaO2 and resulted in a reduction in the incidence of requirement for ECMO; there were not randomized controlled trials regarding the treatment of PPHN by hyperventilation, high-frequency ventilation, alkali infusion, pulmonary vasodilators (magnesium sulfate, tolazoline, prostaglandin or prostacyclin, milrinone), surfactant therapy; oral sildenafil could lower oxygenation index (OI) and result in a reduction in the incidence of death. The individualized treatment plans of oral sildenafil were developed based on the available evidence, existing conditions of the hospital, and the values of children with families. After 1 month of treatment, the FiO2 returned to normal and symptoms were alleviated. Conclusion The treatment efficacies and the survival rates in meconium aspiration syndrome combined with PPHN have been improved by determining an individualized treatment plan according to evidence-based methods.